Cargando…
Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464921/ https://www.ncbi.nlm.nih.gov/pubmed/37433025 http://dx.doi.org/10.1093/ijnp/pyad038 |
Ejemplares similares
-
A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
por: Nani, João V, et al.
Publicado: (2020) -
Corrigendum to “Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema”
por: Rasmussen, Eva Rye, et al.
Publicado: (2018) -
Corrigendum to “Cardioprotective Effects of Qishenyiqi Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin-Converting Enzyme 2”
por: Wang, Yong, et al.
Publicado: (2019) -
Corrigendum to “Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents”
por: Dos Santos-Júnior, Amilton, et al.
Publicado: (2017) -
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]
Publicado: (2022)